- Home
- EPC vs PHVS Comparison
EPC vs PHVS Comparison
Compare EPC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPC
- PHVS
- Stock Information
- Founded
- EPC 1999
- PHVS 2015
- Country
- EPC United States
- PHVS Switzerland
- Employees
- EPC N/A
- PHVS 119
- Industry
- EPC Package Goods/Cosmetics
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- EPC Consumer Discretionary
- PHVS Health Care
- Exchange
- EPC Nasdaq
- PHVS Nasdaq
- Market Cap
- EPC 1.4B
- PHVS 1.4B
- IPO Year
- EPC 2000
- PHVS 2021
- Fundamental
- Price
- EPC $22.02
- PHVS $20.12
- Analyst Decision
- EPC Buy
- PHVS Buy
- Analyst Count
- EPC 7
- PHVS 6
- Target Price
- EPC $29.29
- PHVS $37.17
- AVG Volume (30 Days)
- EPC 957.4K
- PHVS 215.4K
- Earning Date
- EPC 08-05-2025
- PHVS 08-13-2025
- Dividend Yield
- EPC 2.73%
- PHVS N/A
- EPS Growth
- EPC N/A
- PHVS N/A
- EPS
- EPC 1.34
- PHVS N/A
- Revenue
- EPC $2,203,900,000.00
- PHVS N/A
- Revenue This Year
- EPC $0.77
- PHVS N/A
- Revenue Next Year
- EPC $2.47
- PHVS N/A
- P/E Ratio
- EPC $16.40
- PHVS N/A
- Revenue Growth
- EPC N/A
- PHVS N/A
- 52 Week Low
- EPC $19.13
- PHVS $11.51
- 52 Week High
- EPC $40.71
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- EPC 35.22
- PHVS 48.68
- Support Level
- EPC $19.13
- PHVS $19.12
- Resistance Level
- EPC $25.57
- PHVS $22.30
- Average True Range (ATR)
- EPC 0.87
- PHVS 1.22
- MACD
- EPC -0.51
- PHVS -0.23
- Stochastic Oscillator
- EPC 35.86
- PHVS 22.17
About EPC Edgewell Personal Care Company
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.